Cosmo Pharmaceuticals

C43.FPhase 2

Dublin, IrelandFounded 1997cosmopharmaceuticals.com

Cosmo Pharmaceuticals is a publicly traded, revenue-generating biopharmaceutical company with a strategic focus on gastroenterology. Its core expertise lies in the MMX® multi-matrix system, a proprietary technology enabling targeted topical delivery of drugs to the colon. The company's strategy combines the commercialization of its approved products, like Uceris® and Methylene Blue MMX®, with the advancement of its clinical pipeline, including novel candidates for ulcerative colitis and Crohn's disease, while also engaging in strategic licensing and partnership agreements.

Market Cap

$2.2B

Founded

1997

Employees

200-500

Focus

Biotech

C43.F · Stock Price

USD 121.50+107.30 (+755.63%)

Historical price data

AI Company Overview

Technology Platform

MMX® (Multi Matrix System) technology, a proprietary oral drug delivery system designed for targeted topical release of active ingredients in the colon.

Pipeline Snapshot

4 drugs in pipeline

Drug	Indication	Stage
Methylene Blue MMX 25 mg modified release tablets	Colon Staining in Preparation for Colonoscopy	Phase 2
Rifamycin SV 600mg t.i.d. + Rifamycin SV b.i.d. + Placebo + Placebo t.i.d.	Diarrhea-predominant Irritable Bowel Syndrome	Phase 2
400 mg Rifamycin SV dosage + 800 mg Rifamycin SV dosage + 1200 mg Rifamycin SV d...	Infectious Diarrhoea	Phase 2
CB-03-10	Advanced Refractory Solid Tumors	Phase 1

Funding History

IPOUndisclosedUndisclosedJun 15, 2007

Opportunities

Significant growth opportunities exist from the potential US FDA approval and launch of Methylene Blue MMX® for polyp detection, a large and critical market in gastroenterology.

Further pipeline catalysts, including Phase 3 data for Gleto® in diverticulitis, could unlock new therapeutic markets with high unmet need.

Risk Factors

Key risks include clinical trial failures for late-stage pipeline assets, regulatory delays for Methylene Blue MMX® in the US, and commercial execution challenges in a competitive GI market.

The company also faces dependency on licensing partners for a substantial portion of its revenue.

Competitive Landscape

Cosmo competes with large pharma giants in IBD (AbbVie, Takeda, Pfizer) and specialty pharma companies in GI. Its primary differentiation is the proprietary MMX® drug delivery platform for targeted colonic therapy and a focused strategy on niche, high-need gastrointestinal indications.

Publications

Pipeline